新药研发:成都先导与勃林格殷格翰达成基于DNA编码化合物库技术的新药研发合作
中国成都 2017年11月27日 成都先导药物开发有限公司宣布与勃林格殷格翰达成新药研发合作,以期针对勃林格殷格翰关注的靶点发现全新结构的小分子化合物。根据合作协议,成都先导将利用其以DNA编码化合物库设计、合成与筛选为核心的先进技术平台,为勃林格殷格翰筛选新的先导化合物。勃林格殷格翰将依据协议向成都先导支付首付款及后续里程碑款,具体金额未被披露。

中国成都 2017年11月27日  成都先导药物开发有限公司宣布与勃林格殷格翰达成新药研发合作,以期针对勃林格殷格翰关注的靶点发现全新结构的小分子化合物。根据合作协议,成都先导将利用其以DNA编码化合物库设计、合成与筛选为核心的先进技术平台,为勃林格殷格翰筛选新的先导化合物。勃林格殷格翰将依据协议向成都先导支付首付款及后续里程碑款,具体金额未被披露。

 

成都先导董事长兼首席执行官李进博士表示“勃林格殷格翰是一家研发型跨国制药企业,我们很高兴与勃林格殷格翰建立合作,此次合作进一步巩固了成都先导在快速发展的DNA编码化合物库技术领域的地位。我们将与勃林格殷格翰的科研人员紧密合作,共同发现新的先导化合物,促进其新药研发项目的推进,以解决未被满足的医疗需求。”

勃林格殷格翰高级副总裁,Eric Haaksma教授表示“我们也很高兴可以利用成都先导的DNA编码化合物库平台来进一步加强我们在小分子新药开发领域的专业能力。我们相信,成都先导在巨大化合物结构空间的筛选能力,与勃林格殷格翰将苗头化合物优化至临床药物的能力相结合,一定能够加速原创新药的上市进程。”

 

关于成都先导

成都先导是一家创新驱动型生物技术公司。总部位于中国成都,在美国有实验室。成都先导已建立了一个独特的早期新药发现平台,即DNA编码化合物库设计与筛选技术。目前,成都先导基于数百种不同的骨架结构,已经完成逾900亿结构全新、具有多样性和类药性DNA编码化合物的合成,并且已有多个案例证实了其针对已知靶点和新兴靶点筛选苗头化合物的能力。成都先导已与多家制药、生物技术企业以及研究机构建立合作,致力于发现、开发新的治疗方案。

 

获取更多信息,请联系:

李进博士,董事长兼CEO,成都先导药物开发有限公司,电话:+86 28 85197385(分机 8001)

Barry Morgan博士,首席科学官,成都先导药物开发有限公司,电话:+1 5088409646s

 

 

HITGEN andBoehringer Ingelheim Enter DNA-EncodedLibrary Based Drug DiscoveryResearchCollaboration

Chengdu, China,November23rd 2017,HitGen Ltd announced thatthe company has entered into a drug discovery research collaboration with Boehringer Ingelheim to identify novel small molecule leads for targets ofinterest to Boehringer Ingelheim. In this collaboration, HitGen will applyits advanced technology platform, based on DNA-encoded library design,synthesis and screening, to discover novel leads for Boehringer Ingelheim. Under the terms ofthe agreement, HitGen will receive upfront payments, and beeligible for milestone payments from Boehringer Ingelheim. Specific financialdetails were not disclosed.


“We are delighted to enter this collaboration with Boehringer Ingelheim, a major research based pharmaceuticalcompany providing world-wide benefits topatients  Thiscollaboration further emphasizes the role of HitGen in the rapidly developingfield of DNA-encoded chemistry. We will work closely with Boehringer Ingelheim scientists togenerate new lead compounds for their research programmes to address unmetmedical needs.” said Dr. Jin Li, Chairman of the Board and ChiefExecutive Officer of HitGen. 

Prof. Eric Haaksma, Senior Vice President Research Germany, said “We arevery excited about the opportunity to complement our in-house expertise in thefield of small molecule therapeutics research with HitGen’s DNA encoded libraryplatform. We believe that HitGen’s screening capabilities of huge chemicalspaces in combination with Boehringer Ingelheim’s skills in optimizing HitGen’shits to novel drugs could speed-up the provision of innovative medicines.”

 

AboutHitGen Ltd

HitGen is a biotech companywithheadquarters and main research facilities based in Chengdu, China and with laboratory in USA.  HitGenhas established a unique platform for drug discovery research centred around DNA encoded chemical libraries(DELs) . HitGen’sDELscontain more than 90 billion novel, diverse, drug-like small molecule andmacrocycle compounds. These compounds are membersof DELssynthesised from many hundreds of distinct chemical scaffolds, designed with tractablechemistry and proven results for finding drug leads against biological targets from known and novel classes.  HitGen is working with multiple pharmaceutical,biotech companies and research institutes to discover and develop noveltherapeutics of the future.

For further information, pleasecontact

Dr. Jin Li, Chairman & CEO, HitGenLtd. Tel: +86 28 85197385

Dr. Barry Morgan, Chief ScientificOfficer,HitGen Ltd. Tel: +1 5088409646

 


查看更多
发表评论 我在frontend\modules\comment\widgets\views\文件夹下面 test